Researchers have analyzed flotillin levels in samples from individuals with and without Alzheimer’s disease (AD) and determined that serum flotillin levels are negatively associated with brain amyloid deposition. Flotillin could serve as a biomarker to estimate brain amyloid deposition, potentially aiding the early diagnosis of AD.
Browsing: Alzheimer’s disease
A novel protein has been discovered that could be a useful blood-based biomarker to monitor the progression of inherited Alzheimer’s disease, over a decade before the clinical symptoms appear.
Researchers have identified the DAG peptide as a potential biomarker for Alzheimer’s disease development.
The newly designed polygenic hazard score test could allow earlier diagnoses and more successful intervention strategies for Alzheimer’s disease.
Researchers have identified new biomarkers that could aid stage-specific diagnosis of Alzheimer’s, leading to advancements in treatment.
Research funded by the Alzheimer’s society shows potential for the development of a blood test to detect biomarkers as a predictor of Alzheimer’s disease.
European researchers have developed a faster and more affordable method to identify individuals more susceptible to Alzheimer’s disease utilizing a biochip-based blood test.
Researchers have developed a biosensor with nanometric sensitivity that is able to detect peptides linked to neurodegenerative disorders such as Alzheimer’s and Parkinson’s.
Mid-life biomarker changes could predict chances of developing Alzheimer’s disease.
Studying the metabolic profiles of different brain regions could help us better understand neurodegenerative diseases.